IO Biotech
IOBT
IOBT was delisted on the 6th of April, 2026.
27 hedge funds and large institutions have $18.2M invested in IO Biotech in 2024 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 1 increasing their positions, 4 reducing their positions, and 5 closing their positions.
140% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 5
35% more funds holding
Funds holding: 20 → 27 (+7)
5.92% less ownership
Funds ownership: 35.88% → 29.96% (-5.9%)
27% less capital invested
Capital invested by funds: $24.8M → $18.2M (-$6.66M)
75% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LCM
Landscape Capital Management
Englewood,
New Jersey
|
+$440K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$269K |
| 3 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$74.6K |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$59.7K |
| 5 |
Vontobel Holding
Zurich,
Switzerland
|
+$32.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SB
Samsara BioCapital
Palo Alto,
California
|
-$3.82M |
| 2 |
Morgan Stanley
New York
|
-$1.34M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
-$519K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$60.5K |
| 5 |
Two Sigma Investments
New York
|
-$31.5K |
IOBT Hedge Fund Activity: Q4 2024 in Review
27 of the 7,602 institutional investors tracked by Wall St. Rank reported a position in IO Biotech (IOBT) for Q4 2024, worth a combined $18.2M — down 27% from $24.8M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new IOBT positions and 5 closed out — a net gain of 7 holders — while 1 added to existing stakes and 4 trimmed.
The largest buyer was Landscape Capital Management, opening a new position worth an estimated $440K. The largest seller was Samsara BioCapital, exiting entirely with an estimated $3.82M sold.
- 27 institutional investors held IO Biotech (IOBT) as of Q4 2024, up from 20 in Q3 2024.
- Funds reported $18.2M of IO Biotech stock for Q4 2024, down 27% quarter-over-quarter.
- 12 funds opened new IO Biotech positions in Q4 2024 and 5 closed out, a net change of +7 holders.
- The largest IO Biotech buyer in Q4 2024 was Landscape Capital Management, an estimated $440K added.
- The largest IO Biotech seller in Q4 2024 was Samsara BioCapital, an estimated $3.82M sold.
Based on aggregated 13F filings for Q4 2024.